Verge prepares for clinical debut with strategics in $98M series B 

Seeded by tech-focused investors six years ago, Verge’s series B now brings together a diverse syndicate of investors, including two pharmas, as the AI-driven target discovery company plans to enter the clinic in 2022. 

The $98 million round was led by funds managed by BlackRock and includes new investors  Eli Lilly and Co. (NYSE:LLY), Merck Global Health Innovation Fund, Section 32 and Vulcan Capital, along with existing investors including Threshold Ventures, ALS Investment Fund, Tao Capital Partners and Lifeforce capital. ...